ReferenceID	RF_name
REF00005001	Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab. 2024 Aug 6;36(8):1696-1710.e10.
REF00005002	Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC. Adv Sci (Weinh). 2024 Dec;11(46):e2401399.
REF00005003	Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. Adv Sci (Weinh). 2024 Oct;11(38):e2406333.
REF00005004	Histone Lysine Lactylation (Kla)-induced BCAM Promotes OSCC Progression and Cis-Platinum Resistance. Oral Dis. 2025 Apr;31(4):1116-1132.
REF00005005	Aldolase B-driven lactagenesis and CEACAM6 activation promote cell renewal and chemoresistance in colorectal cancer through the Warburg effect. Cell Death Dis. 2023 Oct 10;14(10):660.
REF00005006	Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. Drug Resist Updat. 2023 Jul;69:100976.
REF00005007	Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. J Exp Clin Cancer Res. 2021 May 11;40(1):164.
REF00005008	TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas. Mol Oncol. 2020 Dec;14(12):3030-3047.
REF00005009	Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby Promoting Resistance against Inhibitors of Glutamine Metabolism. Antioxidants (Basel). 2023 Sep 30;12(10):1818.
REF00005010	PPARalpha-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma. Nat Commun. 2025 Feb 1;16(1):1237.
REF00005011	ASPP2 suppresses tumour growth and stemness characteristics in HCC by inhibiting Warburg effect via WNT/beta-catenin/HK2 axis. J Cell Mol Med. 2023 Mar;27(5):659-671.
REF00005012	NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer. Ther Adv Med Oncol. 2021 Jun 30;13:17588359211027836.
REF00005013	Circular RNA circUBE2D2 functions as an oncogenic factor in hepatocellular carcinoma sorafenib resistance and glycolysis. Am J Transl Res. 2021 Jun 15;13(6):6076-6086. eCollection 2021.
REF00005014	Knockdown of FBI-1 Inhibits the Warburg Effect and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents via miR-3692/HIF-1alpha. Front Oncol. 2021 Nov 12;11:796839.
REF00005015	Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization. Cell Death Dis. 2021 May 18;12(6):509.
REF00005016	Elucidating molecular mechanisms of acquired resistance to BRAF inhibitors in melanoma using a microfluidic device and deep sequencing. Genomics Inform. 2021 Mar;19(1):e2.
REF00005017	SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. Nat Commun. 2021 Mar 22;12(1):1812.
REF00005018	URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat Commun. 2023 Oct 7;14(1):6269.
REF00005019	HKDC1 reprograms lipid metabolism to enhance gastric cancer metastasis and cisplatin resistance via forming a ribonucleoprotein complex. Cancer Lett. 2023 Aug 10;569:216305.
REF00005020	Metabolic Plasticity of Glioblastoma Cells in Response to DHODH Inhibitor BAY2402234 Treatment. Metabolites. 2024 Jul 27;14(8):413.
REF00005021	Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer. J Transl Med. 2024 Jul 24;22(1):676.
REF00005022	OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition. Proc Natl Acad Sci U S A. 2024 May 7;121(19):e2315348121.
REF00005023	Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis. Aging (Albany NY). 2024 Jan 10;16(1):627-647.
REF00005024	The roles and mechanisms of TGFB1 in acute myeloid leukemia chemoresistance. Cell Signal. 2024 Apr;116:111027.
REF00005025	Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023 Sep 19;4(9):101162.
REF00005026	Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab. J Natl Cancer Inst. 2022 Dec 8;114(12):1720-1727.
REF00005027	LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis. Nutr Cancer. 2023;75(8):1646-1657.
REF00005028	Proteomic Characterization of a 3D HER2+ Breast Cancer Model Reveals the Role of Mitochondrial Complex I in Acquired Resistance to Trastuzumab. Int J Mol Sci. 2024 Jul 5;25(13):7397.
REF00005029	MIER2/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma. J Adv Res. 2025 Apr;70:287-305.
REF00005030	STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. Research (Wash D C). 2024 Nov 26;7:0539.
REF00005031	Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. Redox Biol. 2024 Jul;73:103207.
REF00005032	Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer. J Transl Med. 2024 Jan 13;22(1):55.
REF00005033	Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity in pancreatic ductal adenocarcinoma. Acta Pharmacol Sin. 2025 Feb 12.
REF00005034	Long noncoding RNA UCA1 inhibits epirubicin-induced apoptosis by activating PPARalpha-mediated lipid metabolism. Exp Cell Res. 2024 Oct 1;442(2):114271.
REF00005035	CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Surgery. 2024 May;175(5):1264-1275.
REF00005036	MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma. J Exp Clin Cancer Res. 2023 Jun 10;42(1):145.
REF00005037	NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature. 2024 Jul;631(8021):663-669.
REF00005038	MicroRNA-18a-5p regulates the Warburg effect by targeting hypoxia-inducible factor 1alpha in the K562/ADM cell line. Exp Ther Med. 2021 Oct;22(4):1069.
REF00005039	PKM1 is involved in resistance to anti-cancer drugs. Biochem Biophys Res Commun. 2016 Apr 22;473(1):174-180.
REF00005040	20(S)-ginsenoside Rh2 ameliorates ATRA resistance in APL by modulating lactylation-driven METTL3. J Ginseng Res. 2024 May;48(3):298-309.
REF00005041	ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2. Int J Mol Sci. 2023 Jun 30;24(13):10938.
REF00005042	Mechanism of Cell Death by Combined Treatment with an xCT Inhibitor and Paclitaxel: An Alternative Therapeutic Strategy for Patients with Ovarian Clear Cell Carcinoma. Int J Mol Sci. 2023 Jul 22;24(14):11781.
REF00005043	Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma. Biomed Pharmacother. 2022 Jun;150:113032.
REF00005044	Shikonin reverses cancer-associated fibroblast-induced gemcitabine resistance in pancreatic cancer cells by suppressing monocarboxylate transporter 4-mediated reverse Warburg effect. Phytomedicine. 2024 Jan;123:155214.
REF00005045	Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell Death Dis. 2024 Feb 12;15(2):131.
REF00005046	SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cells. 2023 Oct 23;12(20):2509.
REF00005047	Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models. Sci Transl Med. 2023 Jan 11;15(678):eabl7895.
REF00005048	Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancer. Cell Oncol (Dordr). 2023 Oct;46(5):1473-1492.
REF00005049	Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts. J Transl Med. 2024 Aug 5;22(1):733.
REF00005050	Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. Mol Oncol. 2024 Sep;18(9):2196-2211.
REF00005051	PDK1- and PDK2-mediated metabolic reprogramming contributes to the TGFbeta1-promoted stem-like properties in head and neck cancer. Cancer Metab. 2022 Dec 6;10(1):23.
REF00005052	Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway. Sci Rep. 2024 Jul 11;14(1):16059.
REF00005053	Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer. Mol Metab. 2022 Nov;65:101576.
REF00005054	N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance. Oncogene. 2024 Jul;43(31):2405-2420.
REF00005055	Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer. FASEB J. 2024 May 31;38(10):e23705.
REF00005056	IDH2 stabilizes HIF-1alpha-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. EMBO J. 2023 Feb 15;42(4):e110620.
REF00005057	HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression. Cell Mol Life Sci. 2022 Jun 4;79(6):343.
REF00005058	MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. Mol Cancer Res. 2022 May 4;20(5):722-734.
REF00005059	Fatty acid synthase inhibitor cerulenin hinders liver cancer stem cell properties through FASN/APP axis as novel therapeutic strategies. J Lipid Res. 2024 Nov;65(11):100660.
REF00005060	De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer. Cancer Lett. 2022 Nov 28;549:215837.
REF00005061	LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM. Mol Cancer. 2024 Jan 24;23(1):23.
REF00005062	N(6)-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming. Theranostics. 2022 Jun 13;12(10):4802-4817.
REF00005063	ROS/PI3K/Akt and Wnt/beta-catenin signalings activate HIF-1alpha-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J Exp Clin Cancer Res. 2022 Jan 8;41(1):15.
REF00005064	CSN6 Mediates Nucleotide Metabolism to Promote Tumor Development and Chemoresistance in Colorectal Cancer. Cancer Res. 2023 Feb 3;83(3):414-427.
REF00005065	Adipocytic Glutamine Synthetase Upregulation via Altered Histone Methylation Promotes 5FU Chemoresistance in Peritoneal Carcinomatosis of Colorectal Cancer. Front Oncol. 2021 Oct 12;11:748730.
REF00005066	Arenobufagin modulation of PCSK9-mediated cholesterol metabolism induces tumor-associated macrophages polarisation to inhibit hepatocellular carcinoma progression. Phytomedicine. 2024 Jun;128:155532.
REF00005067	Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells. Arch Pharm Res. 2023 Dec;46(11-12):907-923.
REF00005068	Ceramide kinase confers tamoxifen resistance in estrogen receptor-positive breast cancer by altering sphingolipid metabolism. Pharmacol Res. 2023 Jan;187:106558.
REF00005069	Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop via NRF2 in cancer therapeutic resistance. Acta Pharm Sin B. 2022 Apr;12(4):1871-1884.
REF00005070	FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity. Cells. 2023 Dec 6;12(24):2777.
REF00005071	NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. Mol Metab. 2024 Feb;80:101876.
REF00005072	Curcumin Synergizes with Cisplatin to Inhibit Colon Cancer through Targeting the MicroRNA-137-Glutaminase Axis. Curr Med Sci. 2022 Feb;42(1):108-117.
REF00005073	ROCK2 increases drug resistance in acute myeloid leukemia via metabolic reprogramming and MAPK/PI3K/AKT signaling. Int Immunopharmacol. 2024 Oct 25;140:112897.
REF00005074	Prognostic implications of metabolism-related genes in acute myeloid leukemia. Front Genet. 2024 Oct 3;15:1424365.
REF00005075	IGF2BP1-regulated expression of ERRalpha is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells. J Transl Med. 2022 Aug 2;20(1):348.
REF00005076	The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2. Cells. 2021 Nov 6;10(11):3059.
REF00005077	NEK6 dampens FOXO3 nuclear translocation to stabilize C-MYC and promotes subsequent de novo purine synthesis to support ovarian cancer chemoresistance. Cell Death Dis. 2024 Sep 10;15(9):661.
REF00005078	Cell calcification reverses the chemoresistance of cancer cells via the conversion of glycolipid metabolism. Biomaterials. 2025 Mar;314:122886.
REF00005079	Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer. Redox Biol. 2023 Jun;62:102686.
REF00005080	Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy. Comput Struct Biotechnol J. 2021 Jul 8;19:4059-4066.
REF00005081	Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner. BMC Cancer. 2021 Oct 17;21(1):1112.
REF00005082	Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation. Oncotarget. 2016 May 3;7(18):25113-24.
REF00005083	Sustained activation of non-canonical NF-kappaB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL. Leukemia. 2023 Feb;37(2):441-452.
REF00005084	AHR signaling pathway mediates mitochondrial oxidative phosphorylation which leads to cytarabine resistance. Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):597-606.
REF00005085	Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect. Hematol Oncol. 2024 Nov;42(6):e3316.
REF00005086	DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB. Transl Oncol. 2024 Aug;46:102016.
REF00005087	Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis. Phytother Res. 2023 Dec;37(12):5837-5853.
REF00005088	EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma. Blood. 2023 Nov 30;142(22):1879-1894.
REF00005089	Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma. Cell Rep Med. 2024 Apr 16;5(4):101484.
REF00005090	Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner. Clin Cancer Res. 2021 Sep 1;27(17):4910-4922.
REF00005091	Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway. Cancer Cell Int. 2024 Jun 28;24(1):224.
REF00005092	HIF-1alpha-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma. J Exp Clin Cancer Res. 2024 Sep 30;43(1):269.
REF00005093	Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. Cancer Res. 2023 Jul 5;83(13):2187-2207.
REF00005094	Long non-coding RNA PXN-AS1 promotes glutamine synthetase-mediated chronic myeloid leukemia BCR::ABL1-independent resistance to Imatinib via cell cycle signaling pathway. Cancer Cell Int. 2024 May 29;24(1):186.
REF00005095	BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP. Cell Death Dis. 2023 Apr 24;14(4):287.
REF00005096	Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells. Cell Commun Signal. 2020 Oct 23;18(1):167.
REF00005097	Metabolic profiling of glioblastoma stem cells reveals pyruvate carboxylase as a critical survival factor and potential therapeutic target. Neuro Oncol. 2024 Sep 5;26(9):1572-1586.
REF00005098	Drug-induced lactate confers ferroptosis resistance via p38-SGK1-NEDD4L-dependent upregulation of GPX4 in NSCLC cells. Cell Death Discov. 2023 May 15;9(1):165.
REF00005099	Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide. Sci Rep. 2021 Jul 8;11(1):14161.
REF00005100	Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention. Adv Sci (Weinh). 2024 May;11(19):e2309290.
REF00005101	Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation. J Biomed Sci. 2022 Mar 25;29(1):21.
REF00005102	Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma. J Neurooncol. 2022 Mar;157(1):15-26.
REF00005103	Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Epirubicin Resistance Through Metabolic Reprograming in Triple-Negative Breast Cancer Cells. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231190737.
REF00005104	Targeting Glutaminolysis Shows Efficacy in Both Prednisolone-Sensitive and in Metabolically Rewired Prednisolone-Resistant B-Cell Childhood Acute Lymphoblastic Leukaemia Cells. Int J Mol Sci. 2023 Feb 8;24(4):3378.
REF00005105	Inhibition of pyruvate carboxylase reverses metformin resistance by activating AMPK in pancreatic cancer. Life Sci. 2023 Aug 15;327:121817.
REF00005106	Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy. Mol Metab. 2022 Jun;60:101496.
REF00005107	Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer. Mol Carcinog. 2024 Jun;63(6):1024-1037.
REF00005108	Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway. Int J Mol Sci. 2022 Aug 6;23(15):8761.
REF00005109	Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-alpha-mediated signaling. Cell Death Dis. 2014 Aug 14;5(8):e1367.
REF00005110	Icariin-Curcumol promotes docetaxel sensitivity in prostate cancer through modulation of the PI3K-Akt signaling pathway and the Warburg effect. Cancer Cell Int. 2023 Sep 2;23(1):190.
REF00005111	Saikosaponin-d mediates FOXG1 to reverse docetaxel resistance in prostate cancer through oxidative phosphorylation. Mutat Res. 2024 Jul-Dec;829:111875.
REF00005112	Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer. Oncogene. 2024 Jun;43(26):2038-2050.
REF00005113	Therapeutic targeting of glutamate dehydrogenase 1 that links metabolic reprogramming and Snail-mediated epithelial-mesenchymal transition in drug-resistant lung cancer. Pharmacol Res. 2022 Nov;185:106490.
REF00005114	The combined inhibition of SLC1A3 and glutaminase in osimertinib-resistant EGFR mutant cells. Biochim Biophys Acta Gen Subj. 2024 Oct;1868(10):130675.
REF00005115	Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Nat Commun. 2024 May 17;15(1):4195.
REF00005116	Histone Methyltransferase NSD2 Activates PKCalpha to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma. Cancer Res. 2023 Oct 13;83(20):3414-3427.
REF00005117	Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration-resistant prostate cancer. Mol Carcinog. 2022 Apr;61(4):397-407.
REF00005118	Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer. Cells. 2020 Nov 24;9(12):2535.
REF00005119	SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Lett. 2024 Aug 10;597:217070.
REF00005120	Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC). Mol Metab. 2022 May;59:101466.
REF00005121	Tumor suppressive miR-99b-5p as an epigenomic regulator mediating mTOR/AR/SMARCD1 signaling axis in aggressive prostate cancer. Front Oncol. 2023 Nov 7;13:1184186.
REF00005122	Glycolysis related lncRNA SNHG3 / miR-139-5p / PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance. Int J Biol Macromol. 2024 Mar;260(Pt 2):129635.
REF00005123	"Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma. Exp Cell Res. 2024 Apr 1;437(1):113977."
REF00005124	Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism. Metabolites. 2024 Mar 19;14(3):170.
REF00005125	Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification. Eur J Med Res. 2024 Apr 15;29(1):236.
REF00005126	Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and gamma-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma. ACS Nano. 2024 Oct 8;18(40):27487-27502.
REF00005127	"TRIM44, a Novel Prognostic Marker, Supports the Survival of Proteasome-Resistant Multiple Myeloma Cells. Cells. 2024 Aug 26;13(17):1431."
REF00005128	Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma. Mol Omics. 2022 Jan 17;18(1):19-30.
REF00005129	Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis. J Exp Clin Cancer Res. 2022 Feb 1;41(1):45.
REF00005130	Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma. Heliyon. 2024 Jun 20;10(13):e33001.
REF00005131	Capsaicin reverses cisplatin resistance in tongue squamous cell carcinoma by inhibiting the Warburg effect and facilitating mitochondrial-dependent apoptosis via the AMPK/AKT/mTOR axis. Cell Biol Int. 2024 Aug;48(8):1097-1110.
REF00005132	Glutamine metabolism controls amphiregulin-facilitated chemoresistance to cisplatin in human chondrosarcoma. Int J Biol Sci. 2023 Oct 9;19(16):5174-5186.
REF00005133	PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway. Int J Mol Sci. 2021 Oct 25;22(21):11492.
REF00005134	Downregulation of miR?106b?3p increases sensitivity to cisplatin in esophageal cancer cells by targeting TGM3. Mol Med Rep. 2021 Jun;23(6):471.
REF00005135	Mortalin/glucose-regulated protein 75 promotes the cisplatin-resistance of gastric cancer via regulating anti-oxidation/apoptosis and metabolic reprogramming. Cell Death Discov. 2021 Jun 11;7(1):140.
REF00005136	Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism. Mol Ther Oncolytics. 2021 Jan 16;20:228-239.
REF00005137	PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism. Acta Pharm Sin B. 2023 Jan;13(1):157-173.
REF00005138	Adrenomedullin induces cisplatin chemoresistance in ovarian cancer through reprogramming of glucose metabolism. J Transl Int Med. 2023 Jul 5;11(2):169-177.
REF00005139	"Inhibition of ACSS2 triggers glycolysis inhibition and nuclear translocation to activate SIRT1/ATG5/ATG2B deacetylation axis, promoting autophagy and reducing malignancy and chemoresistance in ovarian cancer. Metabolism. 2025 Jan;162:156041."
REF00005140	Implication of BAG5 downregulation in metabolic reprogramming of cisplatin-resistant ovarian cancer cells via mTORC2 signaling pathway. Biochim Biophys Acta Mol Cell Res. 2021 Aug;1868(9):119076.
REF00005141	Regulation of mitochondrial complex III activity and assembly by TRAP1 in cancer cells. Cancer Cell Int. 2022 Dec 12;22(1):402.
REF00005142	Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. BMC Cancer. 2021 Feb 17;21(1):174.
REF00005143	ERRalpha promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer. J Exp Clin Cancer Res. 2023 Oct 20;42(1):274.
REF00005144	Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024 Mar;73:101059.
REF00005145	Cellular hierarchy framework based on single-cell/multi-patient sample sequencing reveals metabolic biomarker PYGL as a therapeutic target for HNSCC. J Exp Clin Cancer Res. 2023 Jul 8;42(1):162.
REF00005146	PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming. Mol Carcinog. 2023 Jun;62(6):866-881.
REF00005147	Targeting PTBP1 blocks glutamine metabolism to improve the cisplatin sensitivity of hepatocarcinoma cells through modulating the mRNA stability of glutaminase. Open Med (Wars). 2023 Sep 12;18(1):20230756.
REF00005148	MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing. Cell Death Dis. 2024 Jun 12;15(6):411.
REF00005149	Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma. BMB Rep. 2023 Nov;56(11):600-605.
REF00005150	Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia. J Exp Clin Cancer Res. 2023 Mar 28;42(1):73.
REF00005151	Targeting the SREBP-1/Hsa-Mir-497/SCAP/FASN Oncometabolic Axis Inhibits the Cancer Stem-like and Chemoresistant Phenotype of Non-Small Cell Lung Carcinoma Cells. Int J Mol Sci. 2022 Jun 30;23(13):7283.
REF00005152	Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 Apr 3;29(7):1344-1359.
REF00005153	Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis. Bioengineered. 2022 Mar;13(3):7670-7682.
REF00005154	GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. Theranostics. 2024 Jun 1;14(9):3470-3485.
REF00005155	Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism. Theranostics. 2024 Oct 21;14(18):7088-7110.
REF00005156	"miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line. Genes (Basel). 2022 Aug 1;13(8):1375."
REF00005157	Glycolysis maintains AMPK activation in sorafenib-induced Warburg effect. Mol Metab. 2023 Nov;77:101796.
REF00005158	Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma. Acta Pharmacol Sin. 2023 Mar;44(3):622-634.
REF00005159	Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect. Cancer Sci. 2020 Jun;111(6):2028-2040.
REF00005160	PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell Death Dis. 2022 Feb 4;13(2):118.
REF00005161	The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity. Oncogene. 2022 Feb;41(7):1024-1039.
REF00005162	Lipidomics and transcriptomics analyses of altered lipid species and pathways in oxaliplatin-treated colorectal cancer cells. J Pharm Biomed Anal. 2021 Jun 5;200:114077.
REF00005163	Wnt/beta-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in?colorectal cancer. J Transl Med. 2024 Feb 3;22(1):133.
REF00005164	Antiaging gene Klotho regulates epithelial-mesenchymal transition and increases sensitivity to pemetrexed by inducing lipocalin-2 expression. Oncol Lett. 2021 May;21(5):418.
REF00005165	FAM83B regulates mitochondrial metabolism and anti-apoptotic activity in pulmonary adenocarcinoma. Apoptosis. 2024 Jun;29(5-6):743-756.
REF00005166	Warburg effect enhanced by AKR1B10 promotes acquired resistance to pemetrexed in lung cancer-derived brain metastasis. J Transl Med. 2023 Aug 16;21(1):547.
REF00005167	Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma. Mol Cancer. 2024 Jul 4;23(1):136.
REF00005168	Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20. Cancer Sci. 2021 Sep;112(9):3585-3597.
REF00005169	Inhibition of Glutamine Uptake Improves the Efficacy of Cetuximab on Gastric Cancer. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211045349.
REF00005170	SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis. JCI Insight. 2023 Nov 8;8(21):e167874.
REF00005171	L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase. Exp Cell Res. 2023 May 15;426(2):113568.
REF00005172	Metabolic pathways underlying GATA6 regulating Trastuzumab resistance in Gastric Cancer cells based on untargeted metabolomics. Int J Med Sci. 2020 Oct 23;17(18):3146-3164.
REF00005173	A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway. J Hematol Oncol. 2016 Aug 31;9(1):76.
REF00005174	Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer. Nat Commun. 2022 Nov 22;13(1):7160.
REF00005175	Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancer. Exp Mol Med. 2024 Apr;56(4):1013-1026.
REF00005176	BNIP3-mediated mitophagy boosts the competitive growth of Lenvatinib-resistant cells via energy metabolism reprogramming in HCC. Cell Death Dis. 2024 Jul 5;15(7):484.
REF00005177	Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy. 2024 Jan;20(1):114-130.
REF00005178	ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nat Metab. 2023 Oct;5(10):1765-1786.
REF00005179	SQLE Mediates Metabolic Reprogramming to Promote LN Metastasis in Castration-Resistant Prostate Cancer. Onco Targets Ther. 2021 Jul 24;14:4285-4295.
REF00005180	Disrupting YAP1-mediated glutamine metabolism induces synthetic lethality alongside ODC1 inhibition in osteosarcoma. Cell Oncol (Dordr). 2024 Oct;47(5):1845-1861.
REF00005181	PKMYT1 knockdown inhibits cholesterol biosynthesis and promotes the drug sensitivity of triple-negative breast cancer cells to atorvastatin. PeerJ. 2024 Jul 12;12:e17749.
REF00005182	Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications. Int J Mol Sci. 2023 Oct 26;24(21):15626.
REF00005183	Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer. Cell Death Dis. 2022 Jul 21;13(7):636.
REF00005184	Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq. Breast Cancer Res Treat. 2021 Apr;186(3):677-686.
REF00005185	Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022 Nov 17;140(20):2113-2126.
REF00005186	Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies. Blood Adv. 2024 Oct 22;8(20):5279-5289.
REF00005187	Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma. Cancers (Basel). 2024 Jun 3;16(11):2130.
REF00005188	Mitochondrial Elongation and ROS-Mediated Apoptosis in Prostate Cancer Cells under Therapy with Apalutamide and Complex I Inhibitor. Int J Mol Sci. 2024 Jun 25;25(13):6939.
REF00005189	ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming. Acta Pharmacol Sin. 2023 Nov;44(11):2282-2295.
REF00005190	Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma. Cancer Res. 2023 Jul 5;83(13):2248-2261.
REF00005191	Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 Sep 11;13(6):433-444.
REF00005192	[Targeting microRNA-125b inhibited the metastasis of Alisertib resistance cells through mediating p53 pathway]. Zhonghua Zhong Liu Za Zhi. 2023 Jun 23;45(6):499-507.
REF00005193	Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nat Commun. 2021 Sep 1;12(1):5203.
REF00005194	Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma. Cancer Res. 2021 Jul 15;81(14):3806-3821.
REF00005195	27-Hydroxycholesterol is a specific factor in the neoplastic microenvironment of HCC that causes MDR via GRP75 regulation of the redox balance and metabolic reprogramming. Cell Biol Toxicol. 2022 Apr;38(2):311-324.
REF00005196	Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clin Transl Med. 2024 May;14(5):e1678.
REF00005197	Metabolic reprogramming driven by METTL1-mediated tRNA m7G modification promotes acquired anlotinib resistance in oral squamous cell carcinoma. Transl Res. 2024 Jun;268:28-39.
REF00005198	A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ERalpha expressing primary and metastatic invasive ductal carcinoma. Front Endocrinol (Lausanne). 2023 Apr 18;14:1129162.
REF00005199	Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma. Cell Rep Med. 2024 Sep 17;5(9):101706.
REF00005200	Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma. PLoS One. 2022 Jun 7;17(6):e0269432.
REF00005201	ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia. Leukemia. 2024 Feb;38(2):302-317.
REF00005202	Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun (Lond). 2024 Nov;44(11):1231-1260.
REF00005203	Mimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs. Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):14.
REF00005204	"Stenotrophomonas maltophilia from Nepal Producing Two Novel Antibiotic Inactivating Enzymes, a Class A beta-Lactamase KBL-1 and an Aminoglycoside 6'-N-Acetyltransferase AAC(6')-Iap. Microbiol Spectr. 2022 Aug 31;10(4):e0114322."
REF00005205	A unique compound ameliorating endoplasmic reticulum stress and insulin resistance by binding to beta tubulin. FASEB J. 2024 Nov 15;38(21):e70150.
REF00005206	Trichophyton mentagrophytes ITS Genotype VIII/Trichophyton indotineae Infection and Antifungal Resistance in Bangladesh. J Fungi (Basel). 2024 Nov 5;10(11):768.
REF00005207	A gamma-glutamyl hydrolase lacking the signal peptide confers susceptibility to folates/antifolates in acute lymphoblastic leukemia cells. FEBS Lett. 2022 Feb;596(4):437-448.
REF00005208	Let-7a-3p overexpression increases chemosensitivity to carmustine and synergistically promotes autophagy and suppresses cell survival in U87MG glioblastoma cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6903-6918.
REF00005209	Exploration of the role of the penicillin binding protein 2c (Pbp2c) in inducible beta-lactam resistance in Corynebacteriaceae. Front Microbiol. 2024 May 9;15:1327723.
REF00005210	M2 macrophages secrete CCL20 to regulate iron metabolism and promote daunorubicin resistance in AML cells. Life Sci. 2025 Jan 15;361:123297.
REF00005211	Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines. Cell Oncol (Dordr). 2022 Oct;45(5):1005-1018.
REF00005212	Nodularin-R Synergistically Enhances Abiraterone Against Castrate- Resistant Prostate Cancer via PPP1CA Inhibition. J Cell Mol Med. 2024 Nov;28(22):e70210.
REF00005213	Novel mechanisms of macrolide resistance revealed by in vitro selection and genome analysis in Mycoplasma pneumoniae. Front Cell Infect Microbiol. 2023 May 22;13:1186017.
REF00005214	Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRAS(G12C) inhibitor resistant tumors. Redox Biol. 2024 Dec;78:103419.
REF00005215	Inhibition of Erythromycin and Erythromycin-Induced Resistance among Staphylococcus aureus Clinical Isolates. Antibiotics (Basel). 2023 Mar 2;12(3):503.
REF00005216	Plasmodium falciparum quinine resistance is multifactorial and includes a role for the drug/metabolite transporters PfCRT and DMT1. bioRxiv [Preprint]. 2025 Apr 11:2024.09.27.615529.
REF00005217	Pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay. J Endocrinol Invest. 2024 May;47(5):1101-1117.
REF00005218	Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study. Lancet Microbe. 2023 Dec;4(12):e994-e1004.
REF00005219	Breast cancer cell resistance to hormonal and targeted therapeutics is correlated with the inactivation of the NR6A1 axis. Cancer Drug Resist. 2024 Nov 23;7:48.
REF00005220	Cysteine- and glycine-rich protein 1 predicts prognosis and therapy response in patients with acute myeloid leukemia. Clin Exp Med. 2024 Mar 28;24(1):57.
REF00005221	P-type ATPase zinc transporter Rv3270 of Mycobacterium tuberculosis enhances multi-drug efflux activity. Microbiology (Reading). 2024 Feb;170(2):001441.
REF00005222	Overexpression of outer membrane protein A (OmpA) increases aminoglycoside sensitivity in mycobacteria. BMC Microbiol. 2024 Nov 13;24(1):472.
REF00005223	Identification of STAM-binding protein as a target for the treatment of gemcitabine resistance pancreatic cancer in a nutrient-poor microenvironment. Cell Death Dis. 2024 Sep 6;15(9):657.
REF00005224	Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. Mol Oncol. 2024 Sep;18(9):2196-2211.
REF00005225	Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma. Anticancer Res. 2024 Dec;44(12):5393-5404.
REF00005226	Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1. Phytomedicine. 2024 Jul;129:155656.
REF00005227	AXL and SHC1 confer crizotinib resistance in patient-derived xenograft model of ALK-driven lung cancer. iScience. 2024 Aug 30;27(9):110846.
REF00005228	Ginsenoside Rg3 enhances the anticancer effects of 5-fluorouracil in colorectal cancer and reduces drug resistance and the Hedgehog pathway activation. Arab J Gastroenterol. 2024 Nov;25(4):437-443.
REF00005229	Inhibition of PI3K/Akt/mTOR Signaling Pathway Suppresses 5-Fluorouracil Resistance in Gastric Cancer. Mol Biotechnol. 2024 Dec;66(12):3640-3654.
REF00005230	FOXK2 amplification promotes breast cancer development and chemoresistance. Cancer Lett. 2024 Aug 10;597:217074.
REF00005231	LncRNA-FGD5-AS1 promotes 5-Fu resistance of cervical cancer cells through modulating the miR-130a-3p-YTHDF2 axis. J Chemother. 2024 Dec 6:1-13.
REF00005232	BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN/AKT/beta-catenin pathway. Theranostics. 2024 Oct 21;14(18):7007-7022.
REF00005233	"3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells. Biochem Biophys Res Commun. 2023 Oct 15;677:26-30."
REF00005234	Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study. Thorac Cancer. 2025 Jan;16(2):e15507.
REF00005235	Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2-positive breast cancer. Environ Toxicol. 2024 Jun;39(6):3389-3399.
REF00005236	EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors. Lung Cancer. 2023 Jul;181:107250.
REF00005237	Multicentre Study of Candida parapsilosis Blood Isolates in Turkiye Highlights an Increasing Rate of Fluconazole Resistance and Emergence of Echinocandin and Multidrug Resistance. Mycoses. 2024 Nov;67(11):e70000.
REF00005238	Elucidating the augmented resistance profile of Scedosporium/Lomentospora species to azoles in a cystic fibrosis mimic environment. J Antimicrob Chemother. 2025 Jan 3;80(1):106-115.
REF00005239	Overcoming Irinotecan Resistance by Targeting Its Downstream Signaling Pathways in Colon Cancer. Cancers (Basel). 2024 Oct 15;16(20):3491.
REF00005240	Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110alpha degradation. Oncogene. 2025 Mar;44(8):530-544.
REF00005241	Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells. Cell Biol Int. 2024 Apr;48(4):496-509.
REF00005242	Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD(+) acute myeloid leukemia by inhibiting beta-catenin activity via the PP2A-GSK3beta axis. Cell Commun Signal. 2024 Aug 7;22(1):391.
REF00005243	Targeting BET proteins inhibited the growth of non-small cell lung carcinoma through downregulation of Met expression. Cell Biol Int. 2023 Mar;47(3):622-633.
REF00005244	Combination Treatment of Resistant Acute Promyelocytic Leukemia Cells with Arsenic Trioxide and Anti-Apoptotic Gene Inhibitors. Pharmaceuticals (Basel). 2024 Nov 14;17(11):1529.
REF00005245	Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia. Ann Hematol. 2024 Jun;103(6):1919-1929.
REF00005246	"Dimeric Bis-Benzimidazole-Pyrroles DB2Py(n) - AT-Site-Specific Ligands: Synthesis, Physicochemical Analysis, and Biological Activity. Acta Naturae. 2024 Jan-Mar;16(1):86-100."
REF00005247	CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis. Int J Mol Sci. 2023 Jun 18;24(12):10306.
REF00005248	[Reversal Effect of NVP-BEZ235 on Doxorubicin-Resistance in Burkitt Lymphoma RAJI Cell Line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):476-482.
REF00005249	Integrated analysis of single-cell RNA-seq and bulk RNA-seq revealed key genes for bone metastasis and chemoresistance in prostate cancer. Genes Genomics. 2024 Dec;46(12):1445-1460.
REF00005250	Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy. Front Pharmacol. 2024 Nov 13;15:1482354.
REF00005251	"Novel N,N-Dimethyl-idarubicin Analogues Are Effective Cytotoxic Agents for ABCB1-Overexpressing, Doxorubicin-Resistant Cells. J Med Chem. 2024 Aug 22;67(16):13802-13812."
REF00005252	Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect. Hematol Oncol. 2024 Nov;42(6):e3316.
REF00005253	Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy. Ann Hematol. 2024 Aug;103(8):2853-2863.
REF00005254	Combination therapy of Lapatinib/Letrozole-based protein-vitamin nanoparticles to enhance the therapeutic effectiveness in drug-resistant breast cancer. Colloids Surf B Biointerfaces. 2025 Mar;247:114399.
REF00005255	Dual inhibition of HERs and PD-1 counteract resistance in KRAS(G12C)-mutant head and neck cancer. J Exp Clin Cancer Res. 2024 Nov 20;43(1):308.
REF00005256	"APH(3')-Ie, an aminoglycoside-modifying enzyme discovered in a rabbit-derived Citrobacter gillenii isolate. Front Cell Infect Microbiol. 2024 Jul 30;14:1435123."
REF00005257	Huaier Regulates Oxaliplatin Resistance in Colorectal Cancer by Regulating Autophagy and Inhibiting the Wnt/beta-catenin Signalling Pathway. Front Biosci (Landmark Ed). 2024 Jan 17;29(1):15.
REF00005258	"The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax. Hemato. 2024 Sep;5(3):321-339."
REF00005259	FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. J Clin Invest. 2024 Oct 22;134(23):e173770.
REF00005260	"Elucidation of the mechanisms of fluconazole resistance and repurposing treatment options against urinary Candida spp. isolated from hospitalized patients in Alexandria, Egypt. BMC Microbiol. 2024 Oct 1;24(1):383."
REF00005261	"Low-Dose Perifosine, a Phase II Phospholipid Akt Inhibitor, Selectively Sensitizes Drug-Resistant ABCB1-Overexpressing Cancer Cells. Biomol Ther (Seoul). 2025 Jan 1;33(1):170-181."
REF00005262	"Methotrexate, Hydrocortisone, Vincristine, Sobuzoxane, and Etoposide Is an Effective Option for Relapsed T-cell Prolymphocytic Leukemia with Loss of CD52 Expression after Retreatment with Alemtuzumab. JMA J. 2024 Oct 15;7(4):642-645."
REF00005263	"Bifidobacterium adolescentis is resistant to pyrazinamide, isoniazid, and streptomycin. Sci Rep. 2024 Nov 28;14(1):29562."
REF00005264	beta-Elemene Reverses Gefitinib Resistance in NSCLC Cells by Inhibiting lncRNA H19-Mediated Autophagy. Pharmaceuticals (Basel). 2024 May 14;17(5):626.
REF00005265	PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling. Life Sci Alliance. 2024 Oct 1;7(12):e202402873.
REF00005266	PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway. Cell Death Dis. 2024 Aug 1;15(8):555.
REF00005267	Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC. J Cell Mol Med. 2023 Jul;27(14):2032-2044.
REF00005268	Febuxostat enhances the efficacy of dasatinib by inhibiting ATP-binding cassette subfamily G member 2 (ABCG2) in chronic myeloid leukemia cells. Biomed Pharmacother. 2024 Dec;181:117709.
REF00005269	Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations. Cancers (Basel). 2023 Nov 9;15(22):5354.
REF00005270	Effect of infection by Mycoplasma arginini and Mycoplasma salivarium on the oncogenic properties of lung cancer cell line A549. Biochem Biophys Res Commun. 2024 Dec 3;736:150878.
REF00005271	Mechanism of Drug Resistance to First-Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas. Cancer Rep (Hoboken). 2024 Oct;7(10):e70033.
REF00005272	Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. Clin Cancer Res. 2024 Sep 3;30(17):3855-3867.
REF00005273	ANP32E promotes esophageal cancer progression and paclitaxel resistance via P53/SLC7A11 axis-regulated ferroptosis. Int Immunopharmacol. 2025 Jan 10;144:113436.
REF00005274	Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways. Mol Oncol. 2025 Jan;19(1):81-98.
REF00005275	Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFbeta and Hedgehog signal pathway. Cell Oncol (Dordr). 2024 Dec;47(6):2201-2215.
REF00005276	TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma. BMC Cancer. 2022 Jul 18;22(1):786.
REF00005277	High expression of LncRNA HOTAIR is a risk factor for temozolomide resistance in glioblastoma via activation of the miR-214/beta-catenin/MGMT pathway. Sci Rep. 2024 Oct 31;14(1):26224.
REF00005278	Inhibiting lncRNA NEAT1 Increases Glioblastoma Response to TMZ by Reducing Connexin 43 Expression. Cancer Rep (Hoboken). 2024 Oct;7(10):e70031.
REF00005279	Receptor for Hyaluronan Mediated Motility (RHAMM)/Hyaluronan Axis in Breast Cancer Chemoresistance. Cancers (Basel). 2024 Oct 25;16(21):3600.
REF00005280	Long noncoding RNA UCA1 inhibits epirubicin-induced apoptosis by activating PPARalpha-mediated lipid metabolism. Exp Cell Res. 2024 Oct 1;442(2):114271.
REF00005281	Identification of a novel adjuvant loperamide that enhances the antibacterial activity of colistin against MCR-1-positive pathogens in vitro/vivo. Lett Appl Microbiol. 2023 Feb 16;76(2):ovad025.
REF00005282	Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells. Genes (Basel). 2024 May 20;15(5):648.
REF00005283	Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions. Pharmaceuticals (Basel). 2023 Feb 3;16(2):236.
REF00005284	Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. Cell Prolif. 2023 Jun;56(6):e13420.
REF00005285	The rv2820c K114N mutation is related with capreomycin tolerance. Tuberculosis (Edinb). 2024 Sep;148:102551.
REF00005286	Cantharidin overcomes IL-2Ralpha signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species. J Immunother Cancer. 2024 Jul 14;12(7):e009099.
REF00005287	Identification of Clinical Value and Biological Effects of XIRP2 Mutation in Hepatocellular Carcinoma. Biology (Basel). 2024 Aug 19;13(8):633.
REF00005288	Genetic diversities and drug resistance in Mycobacterium bovis isolates from zoonotic tuberculosis using whole genome sequencing. BMC Genomics. 2024 Nov 1;25(1):1024.
REF00005289	Differential Host Gene Expression in Response to Infection by Different Mycobacterium tuberculosis Strains-A Pilot Study. Microorganisms. 2024 Oct 25;12(11):2146.
REF00005290	Serine/threonine protein kinase mediates rifampicin resistance in Brucella melitensis through interacting with ribosomal protein RpsD and affecting antioxidant capacity. mSystems. 2025 Jan 21;10(1):e0110924.
REF00005291	Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors. Sci Adv. 2024 Mar;10(9):eadn0042.
REF00005292	Loss of ERalpha involved-HER2 induction mediated by the FOXO3a signaling pathway in fulvestrant-resistant breast cancer. Biochem Biophys Res Commun. 2025 Jan;742:151056.
REF00005293	Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells. Front Oncol. 2024 Nov 15;14:1452981.
REF00005294	Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 Jun 7;26(1):95.
REF00005295	"Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. Cancer Res. 2025 Feb 17;85(4):777-790."
REF00005296	A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERalpha-positive luminal breast cancer. Biochem Pharmacol. 2022 Oct;204:115233.
REF00005297	"Role of tcaA, a potential target as a ceftobiprole resistance breaker in MRSA beta-lactam resistance. Int J Antimicrob Agents. 2024 Jul;64(1):107185."
REF00005298	Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. Cell Rep Med. 2024 Feb 20;5(2):101388.
REF00005299	Cancer-associated fibroblasts regulate mitochondrial metabolism and inhibit chemosensitivity via ANGPTL4-IQGAP1 axis in prostate cancer. J Adv Res. 2024 Dec 6:S2090-1232(24)00559-9.
REF00005300	Establishment of prognostic risk model and drug sensitivity based on prognostic related genes of esophageal cancer. Sci Rep. 2022 May 14;12(1):8008.
REF00005301	DYRK2 controls GSTPI expression through ubiquitination and degradation of Twist1 to reduce chemotherapy resistance caused by EMT in breast cancer. J Mol Histol. 2024 Dec 6;56(1):35.
REF00005302	The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Oct 19;52(5):558-566.
REF00005303	"Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis. Acta Pharmacol Sin. 2025 Apr;46(4):1045-1057."
REF00005304	Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon. Cell Mol Life Sci. 2024 Aug 13;81(1):349.
REF00005305	The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma. Blood. 2025 Mar 13;145(11):1164-1181.
REF00005306	16S rRNA methyltransferase KsgA contributes to oxidative stress and antibiotic resistance in Pseudomonas aeruginosa. Sci Rep. 2024 Nov 3;14(1):26484.
REF00005307	Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer. Br J Cancer. 2023 Oct;129(8):1350-1361.
REF00005308	Osteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer. Adv Sci (Weinh). 2025 Jan;12(2):e2407662.
REF00005309	Knockdown of EPS8 expression attenuates the proliferation of enzalutamide-resistant prostate cancer cells. Am J Cancer Res. 2024 Oct 15;14(10):4717-4730.
REF00005310	NRG1 secreted by cancer-associated fibroblasts contributes to enzalutamide resistance in prostate cancer cells. Am J Cancer Res. 2024 Oct 15;14(10):4830-4840.
REF00005311	Shikonin Stimulates Mitochondria-Mediated Apoptosis by Enhancing Intracellular Reactive Oxygen Species Production and DNA Damage in Oral Cancer Cells. J Cell Biochem. 2025 Jan;126(1):e30671.
REF00005312	AUY922 improves sensitivity to sunitinib in clear cell renal cell carcinoma based on network pharmacology and in vitro experiments. Heliyon. 2024 Jul 18;10(14):e34834.
REF00005313	Hsa_circ_0072732 enhances sunitinib resistance of renal cell carcinoma by inhibiting ferroptosis. Discov Oncol. 2024 Nov 23;15(1):700.
REF00005314	The spread of molecular markers of artemisinin partial resistance and diagnostic evasion in Eritrea: a retrospective molecular epidemiology study. Lancet Microbe. 2025 Feb;6(2):100930.
REF00005315	Endoplasmic reticulum and inner nuclear membrane ubiquitin-conjugating enzymes Ubc6 and Ubc7 confer resistance to hygromycin B in Saccharomyces cerevisiae. MicroPubl Biol. 2024 Jul 29;2024:10.17912/micropub.biology.001276.
REF00005316	MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells. Indian J Hematol Blood Transfus. 2024 Oct;40(4):596-603.
REF00005317	Simultaneously Targeting Two Coupled Signalling Molecules in the Mesenchymal Stem Cell Support Efficiently Sensitises the Multiple Myeloma Cell Line H929 to Bortezomib. Int J Mol Sci. 2023 May 2;24(9):8157.
REF00005318	Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer. Mol Oncol. 2025 Feb;19(2):519-539.
REF00005319	Overexpression of HYOU1 is associated with cisplatin resistance and may depend on m(6)A modification in patients with cervical cancer. Oncol Lett. 2024 Nov 26;29(2):77.
REF00005320	Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin. Cell Oncol (Dordr). 2024 Dec;47(6):2349-2366.
REF00005321	Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation. Heliyon. 2024 Jun 25;10(13):e33567.
REF00005322	Forced Overexpression and Knockout Analysis of SLC30A and SLC39A Family Genes Suggests Their Involvement in Establishing Resistance to Cisplatin in Human Cancer Cells. Int J Mol Sci. 2024 Nov 9;25(22):12049.
REF00005323	The acceleration of cisplatin resistance in colorectal cancer by lncRNA NORAD through regulation of miR-106a-5p/Cyclin D1 axis. J Chemother. 2024 Dec 8:1-12.
REF00005324	Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy. Mol Cell Biochem. 2025 May;480(5):3097-3116.
REF00005325	Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer. Br J Cancer. 2022 Oct;127(7):1340-1351.
REF00005326	beta-elemene Ameliorates Cisplatin Resistance of Gastric Cancer via Regulating Exosomal METTL3-m6A-ARF6 Axis. Cell Biochem Biophys. 2025 Jun;83(2):2047-2058.
REF00005327	CHKB-AS1 enhances proliferation and resistance to NVP-BEZ235 of renal cancer cells via regulating the phosphorylation of MAP4 and PI3K/AKT/mTOR signaling. Eur J Med Res. 2023 Dec 14;28(1):588.
REF00005328	The GSK3beta/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors. Cell Death Discov. 2023 Feb 4;9(1):44.
REF00005329	Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism. Theranostics. 2024 Oct 21;14(18):7088-7110.
REF00005330	Allosteric PI3Kalpha Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations. Cancer Discov. 2024 Feb 8;14(2):227-239.
REF00005331	beta1 integrin mediates unresponsiveness to PI3Kalpha inhibition for radiochemosensitization of 3D HNSCC models. Biomed Pharmacother. 2024 Feb;171:116217.
REF00005332	Understanding Drug Resistance of Wild-Type and L38HL Insertion Mutant of HIV-1 C Protease to Saquinavir. Genes (Basel). 2023 Feb 20;14(2):533.
REF00005333	Mechanical forces inducing oxaliplatin resistance in pancreatic cancer can be targeted by autophagy inhibition. Commun Biol. 2024 Nov 27;7(1):1581.
REF00005334	Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase. Nat Commun. 2023 May 30;14(1):3123.
REF00005335	Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors. Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2213146119.
REF00005336	Methylation of PLK-1 Potentially Drives Bendamustine Resistance in Leukemia Cells. J Nippon Med Sch. 2024 May 21;91(2):162-171.
REF00005337	Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge. Cells. 2024 Nov 7;13(22):1847.
REF00005338	Rituximab induces ferroptosis and RSL3 overcomes rituximab resistance in diffuse large B-cell lymphoma cells. Arch Biochem Biophys. 2024 Nov;761:110188.
REF00005339	HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway. Discov Oncol. 2024 Oct 29;15(1):603.
REF00005340	miR-770-5p-induced cellular switch to sensitize trastuzumab resistant breast cancer cells targeting HER2/EGFR/IGF1R bidirectional crosstalk. Turk J Biol. 2024 Feb 5;48(2):153-162.
REF00005341	Calycosin inhibits gemcitabine-resistant lung cancer cells proliferation through modulation of the LDOC1/GNL3L/NFkappaB. Chin J Physiol. 2023 Jul-Aug;66(4):189-199.
REF00005342	Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer. J Pathol. 2023 Oct;261(2):156-168.
REF00005343	Synergistic use of anti-inflammatory ketorolac and gentamicin to target staphylococcal biofilms. J Transl Med. 2024 Jan 25;22(1):102.
REF00005344	Metabolomic screening of radioiodine refractory thyroid cancer patients and the underlying chemical mechanism of iodine resistance. Sci Rep. 2024 May 8;14(1):10546.
REF00005345	Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit treatment na?ve and therapy resistant forms ovarian cancer. NPJ Precis Oncol. 2025 Jul 11;9(1):236.
REF00005346	NAALADL2-AS2 functions as a competing endogenous RNA to regulate apoptosis and drug resistance in DLBCL. Cancer Biol Ther. 2024 Dec 31;25(1):2432690.
REF00005347	Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection. Antivir Ther. 2024 Feb;29(1):13596535221097495.
REF00005348	Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis. Antiviral Res. 2024 Nov;231:106006.
REF00005349	SARS-CoV-2 Resistance to Small Molecule Inhibitors. Curr Clin Microbiol Rep. 2024 Sep;11(3):127-139.
REF00005350	Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 Jul 4;144(1):61-73.
REF00005351	Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections. Diagnostics (Basel). 2023 Sep 30;13(19):3102.
REF00005352	Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors. Sci Rep. 2024 Jul 16;14(1):16363.
REF00005353	FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells. Biomed Pharmacother. 2024 Oct;179:117325.
REF00005354	Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential. J Cell Mol Med. 2024 Jul;28(14):e18539.
REF00005355	"Decoding drug resistant mechanism of V32I, I50V and I84V mutations of HIV-1 protease on amprenavir binding by using molecular dynamics simulations and MM-GBSA calculations. SAR QSAR Environ Res. 2022 Oct;33(10):805-831."
REF00005356	Androgen Receptor Mediates Dopamine Agonist Resistance by Regulating Intracellular Reactive Oxygen Species in Prolactin-Secreting Pituitary Adenoma. Antioxid Redox Signal. 2025 Jun;42(16-18):954-972.
REF00005357	Attenuation of mitochondrial refractory epilepsy in rotenone corneal kindling model of drug resistance by idebenone: An approach to bypass mitochondrial complex I. Epilepsy Res. 2024 Nov;207:107458.
REF00005358	Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma. Br J Pharmacol. 2025 Mar;182(6):1394-1409.
REF00005359	Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms. Front Oncol. 2024 Jul 18;14:1430833.
REF00005360	The Loss-of-Function ATP Binding Cassette Subfamily G Member 2 Polymorphism ABCG2 c.421C>A Reduces Lamotrigine Trough Concentrations in Adults with Epilepsy. Eur J Drug Metab Pharmacokinet. 2025 Jan;50(1):17-22.
REF00005361	PI3Kdelta Inhibition Potentiates Glucocorticoids in B-lymphoblastic Leukemia by Decreasing Receptor Phosphorylation and Enhancing Gene Regulation. Cancers (Basel). 2023 Dec 27;16(1):143.
REF00005362	Aberrant PI3Kdelta splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers. Front Endocrinol (Lausanne). 2023 Aug 21;14:1190479.
REF00005363	The zinc cluster transcription factor Znc1 regulates Rta3-dependent miltefosine resistance in Candida albicans. mSphere. 2024 Jul 30;9(7):e0027024.
REF00005364	Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models. Clin Cancer Res. 2022 Sep 1;28(17):3836-3849.
REF00005365	G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer. PNAS Nexus. 2024 Jan 4;3(1):pgae002.
REF00005366	Lidocaine attenuates TMZ resistance and inhibits cell migration by modulating the MET pathway in glioblastoma cells. Oncol Rep. 2024 May;51(5):72.
REF00005367	Idebenone Attenuates Diabetic Retinopathy by Modulating Autophagy Via Targeting Akt Signaling. Curr Med Chem. 2024 Nov 1.
REF00005368	"Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo. J Pharmacol Exp Ther. 2024 Mar 15;389(1):51-60."
REF00005369	Association of Wild-Type TP53 with Downregulation of Lovastatin Sensitivity in Human Non-Small Cell Lung Cancer Cells. Curr Issues Mol Biol. 2024 Sep 13;46(9):10130-10139.
REF00005370	The Protective Effects of Mcl-1 on Mitochondrial Damage and Oxidative Stress in Imiquimod-Induced Cancer Cell Death. Cancers (Basel). 2024 Sep 2;16(17):3060.
REF00005371	In Vitro Susceptibility and Resistance of Mycoplasma genitalium to Nitroimidazoles. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0000623.
REF00005372	Hemagglutinin Stability Determines Influenza A Virus Susceptibility to a Broad-Spectrum Fusion Inhibitor Arbidol. ACS Infect Dis. 2022 Aug 12;8(8):1543-1552.
REF00005373	Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas. Sci Rep. 2023 Jul 18;13(1):11596.
REF00005374	An efficient gene targeting system using deltaku80 and functional analysis of Cyp51A in Trichophyton rubrum. AMB Express. 2024 Aug 31;14(1):96.
REF00005375	Unlocking the Therapeutic Potential: Sitagliptin's Multifaceted Approach in Drug-Resistant Epilepsy through a Novel Mechanism Inhibiting Protein Kinase C-gamma and a Long-Term Potentiation Pathway. ACS Pharmacol Transl Sci. 2024 May 14;7(6):1856-1863.
REF00005376	Effects of BYL-719 (alpelisib) on human breast cancer stem cells to overcome drug resistance in human breast cancer. Front Pharmacol. 2024 Oct 14;15:1443422.
REF00005377	Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells. Molecules. 2024 Jan 4;29(1):274.
REF00005378	EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer. Hum Cell. 2024 Sep;37(5):1475-1488.
REF00005379	Far upstream element-binding protein 1 confers lobaplatin resistance by transcriptionally activating PTGES and facilitating the arachidonic acid metabolic pathway in osteosarcoma. MedComm (2020). 2023 May 9;4(3):e257.
REF00005380	ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models. Cell Rep. 2024 Oct 22;43(10):114829.
REF00005381	TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer. Cancer Lett. 2025 Feb 1;610:217356.
REF00005382	"Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. Ann Oncol. 2025 Jan;36(1):54-64."
REF00005383	RNF38 promotes gilteritinib resistance in acute myeloid leukemia via inducing autophagy by regulating ubiquitination of LMX1A. Cell Biol Toxicol. 2024 Nov 28;40(1):105.
REF00005384	Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment. Int J Mol Sci. 2023 Aug 23;24(17):13082.
REF00005385	Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma. Cancers (Basel). 2024 Jun 3;16(11):2130.
REF00005386	Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia. Cancer Cell Int. 2023 Aug 11;23(1):161.
REF00005387	"K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine. Viruses. 2024 Sep 20;16(9):1493."
REF00005388	YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers. Clin Cancer Res. 2025 Mar 17;31(6):1127-1141.
REF00005389	Targeting abatacept-resistant T-helper-17 cells by aldehyde dehydrogenase inhibition. iScience. 2023 Dec 9;27(1):108646.
REF00005390	Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications. Int J Mol Sci. 2023 Oct 26;24(21):15626.
REF00005391	PI3K/Akt inhibition promotes AR activity and prostate cancer cell proliferation through p35-CDK5 modulation. Biochim Biophys Acta Mol Basis Dis. 2025 Feb;1871(2):167568.
REF00005392	Inhibitors targeting the autophosphorylation of serine/threonine kinase of Streptococcus suis show potent antimicrobial activity. Front Microbiol. 2022 Sep 2;13:990091.
REF00005393	Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma. Nat Commun. 2024 Apr 23;15(1):3422.
REF00005394	Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells. Cell Death Dis. 2023 Dec 6;14(12):799.
REF00005395	Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. Int J Clin Oncol. 2023 May;28(5):654-663.
REF00005396	Selumetinib overcomes ITGA2-induced 5-fluorouracil resistance in colorectal cancer. Int Immunopharmacol. 2024 Aug 20;137:112487.
REF00005397	EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma. Front Med (Lausanne). 2024 Nov 13;11:1464610.
REF00005398	Establishment of prognosis model of hepatocellular carcinoma based on prognosis related gene analysis and study on gene regulation mechanism of model. Heliyon. 2024 Sep 30;10(21):e38729.
REF00005399	The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. Cancer Drug Resist. 2024 Oct 18;7:40.
REF00005400	Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant Lung Cancer. Oxid Med Cell Longev. 2022 Jun 20;2022:1112987.
REF00005401	Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase. Sci Transl Med. 2022 Aug 3;14(656):eabn3231.
REF00005402	BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. Cell Rep. 2022 Feb 15;38(7):110374.
REF00005403	USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition. Adv Sci (Weinh). 2024 Sep;11(34):e2401171.
REF00005404	Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells. Cancer Sci. 2024 Oct;115(10):3333-3345.
REF00005405	"CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. Biomol Biomed. 2024 Dec 11;25(1):42-61."
REF00005406	"BI-847325, a selective dual MEK and Aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture. Cancer Cell Int. 2022 Dec 8;22(1):388."
REF00005407	PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin. J Pediatr Surg. 2024 Jul;59(7):1334-1341.
REF00005408	BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms. Int J Cancer. 2024 Mar 15;154(6):1057-1072.
REF00005409	Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib). Cell Commun Signal. 2024 Aug 23;22(1):410.
REF00005410	CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells. Transl Cancer Res. 2024 Jul 31;13(7):3695-3703.
REF00005411	NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a beta2AR-Akt feedback loop that activates autophagy. Mol Oncol. 2022 Aug;16(15):2881-2895.
REF00005412	Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin. Am J Chin Med. 2023;51(8):2221-2241.
REF00005413	Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein. Int J Mol Sci. 2024 Aug 2;25(15):8471.
REF00005414	Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer. J Cancer. 2023 May 29;14(9):1592-1604.
REF00005415	Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming. Pharmacol Res. 2022 Apr;178:106148.
REF00005416	Single Amino Acid Substitution Within the Helicase of Varicella Zoster Virus Makes It Resistant to Amenamevir. J Med Virol. 2024 Nov;96(11):e70080.
REF00005417	TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas. Neuro Oncol. 2025 Mar 7;27(3):727-742.
REF00005418	"Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. Mol Oncol. 2025 Feb;19(2):377-390."
REF00005419	The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism. Cell Oncol (Dordr). 2024 Oct;47(5):1811-1829.
REF00005420	Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. bioRxiv [Preprint]. 2023 May 23:2023.05.23.540590.
REF00005421	Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells. Med Sci (Basel). 2022 May 26;10(2):28.
REF00005422	Coccinic acid exhibits anti-tumor efficacy against NSCLC harboring EGFR L858R/T790M mutation via the EGFR/STAT3 pathway. Bioorg Chem. 2025 Jan;154:108038.
REF00005423	[Study on mechanism of Chinese Yam polysaccharide synergizing nucleoside analogues against hepatitis B virus through p38 MAPK signaling pathway]. Zhongguo Zhong Yao Za Zhi. 2024 May;49(10):2776-2782.
REF00005424	FTY720 increases paclitaxel efficacy in cisplatin-resistant oral squamous cell carcinoma. J Oral Pathol Med. 2024 Jan;53(1):42-52.
REF00005425	"Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters. Toxicol Appl Pharmacol. 2024 Mar;484:116866."
REF00005426	Guggulsterone from Commiphora mukul potentiates anti-glioblastoma efficacy of temozolomide in vitro and in vivo via down-regulating EGFR/PI3K/Akt signaling and NF-kappaB activation. J Ethnopharmacol. 2023 Jan 30;301:115855.
REF00005427	JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL. J Exp Med. 2025 Jan 6;222(1):e20230681.
REF00005428	"PI3Kdelta activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas. Blood Adv. 2024 Dec 24;8(24):6268-6281."
REF00005429	ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms. Mol Cancer Ther. 2024 Mar 4;23(3):368-380.
REF00005430	TNF-alpha exacerbates SARS-CoV-2 infection by stimulating CXCL1 production from macrophages. PLoS Pathog. 2024 Dec 9;20(12):e1012776.
REF00005431	Anti-Tumor Immunity to Patient-Derived Breast Cancer Cells by Vaccination with Interferon-Alpha-Conditioned Dendritic Cells (IFN-DC). Vaccines (Basel). 2024 Sep 17;12(9):1058.
REF00005432	Synergistic combination effect of the PCA-1/ALKBH3 inhibitor HUHS015 on prostate cancer drugs in vitro and in vivo. Anticancer Drugs. 2025 Jan 1;36(1):19-27.
REF00005433	Novel strategies in HPV?16?related cervical cancer treatment: An in vitro study of combined siRNA-E5 with oxaliplatin and ifosfamide chemotherapy. Gene. 2025 Jan 10;932:148904.
REF00005434	Topical histone deacetylase inhibitor remetinostat improves IMQ-induced psoriatic dermatitis via suppressing dendritic cell maturation and keratinocyte differentiation and inflammation. Eur J Pharmacol. 2024 Nov 15;983:177011.
REF00005435	A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells. Mol Divers. 2025 Jun;29(3):2433-2444.
REF00005436	Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res. 2023 Dec 15;83(24):4161-4178.
REF00005437	N6-(2-hydroxyethyl)-adenosine (HEA) exhibits antitumor activity for osteosarcoma progression by regulating IGF1 signaling. Fitoterapia. 2025 Jan;180:106319.
REF00005438	Nepetin limits NLRP3 inflammasome activation and alleviates NLRP3-driven inflammatory diseases via PINK1-dependent mitophagy. Free Radic Biol Med. 2025 Feb 1;227:420-433.
REF00005439	Polyethylene glycol loxenatide modulates lipid metabolism and insulin resistance through lncRNA steroid receptor RNA activator/cellular nucleic acid binding protein/Rho-associated coiled-coil kinase 2 axis in type 2 diabetes mellitus. J Diabetes Investig. 2025 Apr;16(4):715-727.
REF00005440	DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood. 2023 Sep 14;142(11):973-988.
REF00005441	Targeting CCR7-PI3Kgamma overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. Sci Transl Med. 2023 Jun 28;15(702):eabo3826.
REF00005442	Sensitivity analysis and point mutations in BcSDHB confer cyclobutrifluram resistance in Botrytis cinerea from China. Pestic Biochem Physiol. 2024 May;201:105884.
REF00005443	Suppression of TLR signaling by IRAK-1 and -4 dual inhibitor decreases TPF-resistance-induced pro-oncogenic effects in HNSCC. 3 Biotech. 2023 Jan;13(1):14.
REF00005444	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 2022 Apr;3(4):402-417.
REF00005445	Peimine promotes microglial polarization to the M2 phenotype to attenuate drug-resistant epilepsy through suppressing the TLR4/NF-kappaB/HIF-1alpha signaling pathway in a rat model and in BV-2 microglia. Heliyon. 2024 Jul 20;10(15):e34987.
REF00005446	Quinic acid enhances kanamycin efficacy against methicillin-resistant Staphylococcus aureus biofilms. Microb Pathog. 2025 Jan;198:107145.
REF00005447	Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway. Discov Oncol. 2024 Nov 25;15(1):709.
REF00005448	An Optimized Marinopyrrole A Derivative Targets 6-Phosphoglucosamine Synthetase to Inhibit Methicillin-Resistant Staphylococcus aureus. ACS Cent Sci. 2024 Oct 25;10(11):2090-2098.
REF00005449	A novel alpha-mangostin derivative synergistic to antibiotics against MRSA with unique mechanisms. Microbiol Spectr. 2024 Nov 7;12(12):e0163124.
REF00005450	Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. Cancer Res Commun. 2024 Feb 8;4(2):337-348.
REF00005451	Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. Cancer Med. 2024 Jun;13(12):e7393.
REF00005452	The superiority of PMFs on reversing drug resistance of colon cancer and the effect on aerobic glycolysis-ROS-autophagy signaling axis. Oncol Res. 2024 Nov 13;32(12):1891-1902.
REF00005453	Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer. Carcinogenesis. 2023 Aug 18;44(6):497-510.
REF00005454	Development of triazole-based PKC-inhibitors to overcome resistance to EGFR inhibitors in EGFR-mutant lung cancers. Am J Cancer Res. 2023 Oct 15;13(10):4693-4707. eCollection 2023.